A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33862829

about

Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.Pancreatic cancer: chemotherapy and radiotherapy.Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model.Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer.Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.Cellular redox pathways as a therapeutic target in the treatment of cancer.Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.

P2860

Q26740191-6FB4C5C4-A9ED-46F2-9AFF-874FC7B40C37 Q34077774-0E97F355-00D1-4E1A-9D7D-752856F20454 Q34329957-E725203C-8E07-40EA-A1B6-DA702885AF73 Q34720428-27D50F3D-F9CB-4E1F-A741-02E4C3A62FEF Q35857055-A6F2C49C-AA6F-40CE-A243-A90DDE3E94C7 Q35883238-D5B7FCB5-69D4-47C1-9791-8CF06754EC37 Q35913523-03380B3D-B34A-4B93-89D1-28D4CE277D88 Q37004328-0B8A097B-45F6-40A1-9441-12D8192A94F7 Q37699339-C2AC20F5-BC06-4472-B093-A88A77139D08 Q37845832-B6A32BE0-8250-4452-9F55-74D39D0F12A7 Q37910897-608FF098-C5A1-4BD0-A83F-28D7375DD82F Q42040315-391BC3C8-63C9-4696-949C-D41DE2A1D3D5

P2860

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33862829

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@ast

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@en

type

label

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@ast

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@en

prefLabel

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@ast

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@en

P1433

Q33862829-F9A35401-6959-4E86-A32B-1D1B834812FA

P1476

Q33862829-51010D59-41B2-4122-BA66-83E9291FF6F9

P2093

Q33862829-134E250B-2D04-42C5-B52A-54D1FD9FF667

Q33862829-28E13B9A-B348-4BF7-AA29-2362361A3205

Q33862829-3391C6E5-BE0F-4BB2-8BC9-2BF48500ECC3

Q33862829-4A12E5CB-5D49-4F3F-AB8D-3E1DA9206C33

Q33862829-827F008A-391E-4E7B-AFC4-E46314DB2666

Q33862829-82AC4F62-82C0-4C36-AEE5-99D8CE0AB37A

Q33862829-AB9651F7-40BA-4182-8DE8-58CBE705AAC9

Q33862829-FDACE762-AE55-4966-B9EF-E550413A98A8

Q33862829-FFFFB9E5-BC5B-4C02-8443-D6915B9BCC7B

P2860

Q33862829-195E61E5-F0D2-4D53-8FCA-B59538C42F8F

Q33862829-19EDBFAD-B3AB-4783-989C-6235C2EF11E4

Q33862829-28E3447E-5B29-46D7-83C0-301643EF4104

Q33862829-42139F7D-330E-4957-B945-DE10324901A4

Q33862829-4AD246F1-C177-42C4-907D-B381AED37443

Q33862829-532E34AC-E5D8-478C-9534-1227541BD311

Q33862829-A39D5323-A131-410E-B9B3-1F2D8B3E2951

Q33862829-B7F638F4-8D15-4E4C-8B05-B59980B444DD

Q33862829-BE25ABE3-1D5E-4B9A-8E4F-8B04D4D4BC2B

Q33862829-D65AFA70-793D-41C0-9199-FFB47E66B9F3

P2888

Q33862829-25FBBD0A-4FA1-4431-A7E4-19E75DEFF9A6

P304

Q33862829-434696DF-304D-4DD3-A617-E5A15173EAF0

P31

Q33862829-DA9F18CF-027E-4117-950C-31AB6877A383

P356

Q33862829-92B6673C-A786-44F3-947F-57889A97BCB6

P433

Q33862829-08683DFB-3D34-4F4C-BF09-72116CF31971

P478

Q33862829-890C85CF-92C7-49EC-8B3C-D740D5A4BF84

P577

Q33862829-2DEA6CE6-DFB8-4922-93AA-ACDAC9F8E87C

P5875

Q33862829-EA18D600-FEEC-4AB6-B40E-4BFB58C833B1

P6179

Q33862829-6B3B627F-4A4B-4A9F-9D87-8D5FBFFD20CF

P698

Q33862829-9397168D-B0E5-409D-9A50-C1B89B9B41F3

P932

Q33862829-8715CD35-566C-439F-AD72-EA82A04756FF

P356

S00280-009-1162-Y

P1433

Cancer Chemotherapy and Pharmacology

P1476

A phase I study of imexon plus ...... or advanced pancreatic cancer.

@en

P2093

Evan M Hersh

http://www.w3.org/2001/XMLSchema#string

Manuel R Modiano

http://www.w3.org/2001/XMLSchema#string

Mark M Zalupski

http://www.w3.org/2001/XMLSchema#string

Michelle L Boytim

http://www.w3.org/2001/XMLSchema#string

Paul Conkling

http://www.w3.org/2001/XMLSchema#string

Peg Davis

http://www.w3.org/2001/XMLSchema#string

Robert T Dorr

http://www.w3.org/2001/XMLSchema#string

Steven J Cohen

http://www.w3.org/2001/XMLSchema#string

Yehuda Z Patt

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.

P2888

s00280-009-1162-y

P304

287-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-009-1162-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38035379

http://www.w3.org/2001/XMLSchema#string

P6179

1009606003

http://www.w3.org/2001/XMLSchema#string

P698

19855966

http://www.w3.org/2001/XMLSchema#string

P932

2873145

http://www.w3.org/2001/XMLSchema#string